Uterine sarcoma: prognostic factors and treatment evaluation

Area of Science:

• Gynecologic Oncology
• Malignant Uterine Tumors
• Cancer Epidemiology

Background:

• Uterine sarcoma is a rare but highly malignant group of uterine tumors, accounting for 2-6% of all uterine malignancies.
• Common subtypes include endometrial stromal sarcoma, leiomyosarcoma, and carcinosarcoma.
• Limited data exists on risk factors, disease course, and optimal treatment for uterine sarcoma.

Purpose of the Study:

• To evaluate outcomes of uterine sarcoma patients treated at an Israeli tertiary referral center.
• Analysis covered a 20-year period from 1980 to 2005.
• Investigate prognostic factors and treatment efficacy in uterine sarcoma.

Main Methods:

• Retrospective review of 40 uterine sarcoma patient charts.
• Data collected included tumor characteristics, diagnostic stage, treatment modalities, follow-up duration, and survival rates.
• Statistical analysis to correlate disease stage with survival.

Main Results:

• The mean patient age was 53 years; leiomyosarcoma (55%) was the most common type.
• Half of patients presented with Stage I disease; 44% experienced recurrence within 44 months follow-up.
• Five-year survival was 73.1% for Stages I-II and 22.2% for Stages III-IV.

Conclusions:

• Disease stage at diagnosis is the primary prognostic factor for uterine sarcoma.
• Despite diagnostic and therapeutic advancements, survival rates for uterine sarcoma have remained stagnant over the past 25 years.